Funding

Sensible Biotechnologies

United Kingdom · Biotech

A platform for designing and manufacturing naturally modified mRNA medicines.

Visit sensible.bioFunding history

Product

Sensible Biotechnologies combines AI-enabled mRNA design with production of naturally modified mRNA in living cells. Its VECTOR platform is designed to address limitations of conventional synthetic mRNA manufacturing and support a broader range of therapeutic applications. The company is building clinical-grade manufacturing capabilities as it advances the platform.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A$47MBacked VC — ParticipantBlueYard Capital — ParticipantCivilization Ventures — ParticipantIsomer Capital — ParticipantKaya VC — ParticipantOTB Ventures — ParticipantRecode Ventures — ParticipantTech Horizons — ParticipantY Combinator (YC) — Participant

Investors

Backed VCJoined Series ABlueYard CapitalJoined Series ACivilization VenturesJoined Series AIsomer CapitalJoined Series AKaya VCJoined Series AOTB VenturesJoined Series ARecode VenturesJoined Series ATech HorizonsJoined Series AY Combinator (YC)Joined Series A

Coverage

Oct 6, 2026Sensible Biotechnologies · Series A

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesbiospace.com ↗